drugset / Trial / NCT04457765

Betadine Effect on Nasal Mucosa Cilia

NCT04457765

Phase 0 Withdrawn Boston Medical Center
NaSingle-groupOpen-labelBasic science

Summary

The goal of the proposed study is to identify PVP-I at 1.25% as an appropriate intranasal topical preparation for patients undergoing rhinoplasty with no effect on the nasal mucosa cilia (NMC) or olfaction using the saccharin transit time (STT) test as a method for evaluating NMC function. PVP-I has been shown to be viricidal in the upper aerodigestive tract. This study is highly-relevant, as protection for individuals with a high risk of exposure to respiratory pathogens has become increasingly important in the setting of recent viral epidemics such as SARS-CoV-2. Septorhinoplasty is commonly performed throughout the world and there is a paucity of standardized testing in surgical facilities. Much of our understanding of the current COVID-19 pandemic is extrapolated from MERS and SARS data. It is our hope that this study's relevance for the current pandemic remains so in the unfortunate event of another pandemic in the future.

Timeline

Start
2021-04
Primary completion
2022-09
Completion
2022-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Povidone-Iodine Other / unclassified 1.25 % Intranasal
Subject Povidone-Iodine Other / unclassified 240 ml Intranasal

Indications

No indication recorded.